CCXI ChemoCentryx, Inc. Stock Quote

CCXI [NASD]

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	0.60%	Shs Outstand	69.79M	Perf Week	0.29%
Market Cap	2.45B	Forward P/E	-	EPS next Y	-2.17	Insider Trans	-90.38%	Shs Float	57.61M	Perf Month	92.38%
Income	-122.90M	PEG	-	EPS next Q	-0.45	Inst Own	64.70%	Short Float	6.76%	Perf Quarter	137.76%
Sales	21.60M	P/S	113.30	EPS this Y	13.60%	Inst Trans	-0.28%	Short Ratio	0.82	Perf Half Y	-24.68%
Book/sh	4.73	P/B	7.31	EPS next Y	-9.70%	ROA	-24.30%	Target Price	71.00	Perf Year	-33.57%
Cash/sh	4.42	P/C	7.83	EPS next 5Y	-	ROE	-33.20%	52W Range	9.53 - 70.29	Perf YTD	-44.17%
Dividend	-	P/FCF	-	EPS past 5Y	4.80%	ROI	-13.50%	52W High	-50.61%	Beta	1.75
Dividend %	-	Quick Ratio	5.70	Sales past 5Y	-	Gross Margin	-	52W Low	264.27%	ATR	2.89
Employees	133	Current Ratio	5.70	Sales Q/Q	-96.40%	Oper. Margin	-	RSI (14)	67.06	Volatility	7.11% 10.94%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	-292.40%	Profit Margin	-	Rel Volume	0.23	Prev Close	34.57
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Aug 09 AMC	Payout	-	Avg Volume	4.75M	Price	34.72
Recom	2.20	SMA20	23.18%	SMA50	68.13%	SMA200	6.67%	Volume	656,920	Change	0.42%

Oct-11-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$64

Oct-11-21

Upgrade

JP Morgan

Underweight → Neutral

$14 → $38

Oct-08-21

Upgrade

Raymond James

Outperform → Strong Buy

$62 → $107

Oct-08-21

Upgrade

Piper Sandler

Neutral → Overweight

Jul-07-21

Upgrade

Stifel

Hold → Buy

$26 → $31

May-07-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

May-07-21

Downgrade

Stifel

Buy → Hold

$93 → $26

May-07-21

Downgrade

Raymond James

Strong Buy → Outperform

May-07-21

Downgrade

Piper Sandler

Overweight → Neutral

$80 → $25

May-07-21

Downgrade

JP Morgan

Neutral → Underweight

$57 → $17

Mar-02-21

Reiterated

H.C. Wainwright

Buy

$83 → $101

Mar-02-21

Initiated

Stifel

Buy

$93

Oct-29-20

Downgrade

JP Morgan

Overweight → Neutral

$63 → $60

Jun-17-20

Initiated

BTIG Research

Buy

$70

May-27-20

Initiated

Wells Fargo

Overweight

$79

May-12-20

Reiterated

H.C. Wainwright

Buy

$60 → $69

Jan-24-20

Reiterated

H.C. Wainwright

Buy

$40 → $60

Nov-26-19

Reiterated

Piper Jaffray

Overweight

$17 → $54

Nov-26-19

Reiterated

H.C. Wainwright

Buy

$23 → $40

Mar-27-19

Upgrade

B. Riley FBR

Neutral → Buy

$12.50 → $22

Oct-14-21 07:18AM	Is It Too Late to Buy ChemoCentryx Stock? Motley Fool
Oct-13-21 10:00AM	2 Super-Charged Growth Stocks to Buy Now Motley Fool
Oct-11-21 07:43PM	3 Strong Buy Stocks Raymond James Predicts Will Rally Over 60% TipRanks +5.44%
08:38AM	Company News for Oct 11, 2021 Zacks
08:30AM	ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer GlobeNewswire
04:21AM	5 Stocks To Watch For October 11, 2021 Benzinga
02:27AM	ChemoCentryx Receives FDA Approval for TAVNEOS; Shares Skyrocket SmarterAnalyst
Oct-09-21 09:19AM	Is ChemoCentryx, Inc. (NASDAQ:CCXI) Trading At A 41% Discount? Simply Wall St.
Oct-08-21 05:57PM	After half-billion dollars, nearly quarter century, Peninsula biotech lands its first FDA drug approval American City Business Journals +95.97%
05:40PM	Why ChemoCentryx Stock Skyrocketed Today Motley Fool
04:26PM	ChemoCentryx Up Most Since 2019 on Autoimmune Drug Approval Bloomberg
02:50PM	Sundial Growers stock rises, ChemoCentryx soars as Home Depot & Lowe's shares slip Yahoo Finance Video
02:36PM	Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher Benzinga
01:10PM	ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks Motley Fool
12:53PM	ChemoCentryx Shares Are Spiking After an Unexpected FDA Approval Barrons.com
12:20PM	EXCLUSIVE: ChemoCentryx Plans To Start Phase 3 Avacopan Trial In Chronic Skin Disorder In 2022 Benzinga
12:05PM	ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis Zacks
12:03PM	28 Stocks Moving In Friday's Mid-Day Session Benzinga
08:24AM	ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug MarketWatch
08:04AM	5 Top Stock Gainers for Friday: ChemoCentryx, Plug Power, Quidel TheStreet.com
07:28AM	UPDATE 3-ChemoCentryx's drug gets U.S. FDA nod for treating rare autoimmune disease Reuters
07:22AM	ChemoCentryx (CCXI) Soars 5.4%: Is Further Upside Left in the Stock? Zacks
07:04AM	ChemoCentryx Stock Leaps as FDA Approves Vasculitis Drug TheStreet.com
07:00AM	ChemoCentryx Announces FDA Approval of TAVNEOS (avacopan) in ANCA-Associated Vasculitis GlobeNewswire
Sep-27-21 08:30AM	ChemoCentryx Announces Approval in Japan of TAVNEOS (Avacopan) for the Treatment of ANCA-Associated Vasculitis GlobeNewswire +5.55%
Sep-21-21 01:10PM	Heres Why ChemoCentryx (CCXI) Landed in Wasatch Small Caps Detractor List Insider Monkey
Sep-20-21 02:06AM	Should You Be Tempted To Sell ChemoCentryx (CCXI) Stock? Insider Monkey
Sep-16-21 09:11AM	2 Growth Stocks That Could Take Off Before the End of the Year Motley Fool
Sep-15-21 09:47AM	Is the Options Market Predicting a Spike in ChemoCentryx (CCXI) Stock? Zacks
Sep-08-21 11:30AM	ChemoCentryx (CCXI) Up 10.5% Since Last Earnings Report: Can It Continue? Zacks
Sep-02-21 08:30AM	ChemoCentryx to Participate in Two Upcoming Investor Conferences GlobeNewswire
Aug-11-21 08:27AM	Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock? Zacks
01:29AM	Newsflash: ChemoCentryx, Inc. (NASDAQ:CCXI) Analysts Have Been Trimming Their Revenue Forecasts Simply Wall St.
Aug-10-21 10:54AM	ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down Zacks
08:01AM	ChemoCentryx, inc (CCXI) Q2 2021 Earnings Call Transcript Motley Fool
Aug-09-21 05:55PM	ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM	ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights GlobeNewswire
Aug-06-21 01:54PM	Lifshitz Law Firm, P.C. Announces Investigations of 3D Systems Corp. (NYSE: DDD), Acadia Pharmaceuticals, Inc. (NasdaqGS: ACAD), ChemoCentryx, Inc. (NasdaqGS: CCXI), and Peloton Interactive, Inc (NasdaqGS: PTON) GlobeNewswire
Aug-04-21 08:30AM	ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Aug-02-21 03:01PM	Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for Zacks
08:30AM	ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021 GlobeNewswire
Jul-27-21 06:13AM	2 Beaten-Down Biotech Stocks That Could Bounce Back Motley Fool
Jul-21-21 04:24AM	Hedge Funds Are Selling ChemoCentryx Inc (CCXI) Insider Monkey
Jul-10-21 06:44AM	Is Now the Time to Buy ChemoCentryx Stock? Motley Fool
Jul-09-21 04:31PM	Chemocentryx: A Risky Yet Potentially Lucrative Bet TipRanks +11.06%
Jul-08-21 02:25AM	ChemoCentryx (NASDAQ:CCXI) Is Using Debt Safely Simply Wall St.
Jul-07-21 11:14PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI GlobeNewswire
09:30AM	ChemoCentryx (CCXI) Files Amendment to NDA for Avacopan Zacks
08:21AM	(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? PR Newswire
Jul-06-21 03:21PM	LAWSUITS FILED AGAINST CCXI, UI and PRVB - Jakubowitz Law Pursues Shareholders Claims ACCESSWIRE +6.60%
02:35PM	INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of ARRY, CCXI, PCT, WISH Investors, Lead Plaintiff Deadlines Set ACCESSWIRE
10:03AM	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - (CCXI) Newsfile
10:00AM	CCXI Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds ChemoCentryx, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 6, 2021 GlobeNewswire
09:47AM	CCXI Final Deadline Today: Rosen, a Longstanding and Trusted Firm, Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6 Deadline in Securities Class Action - CCXI Newsfile
09:17AM	ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7 Benzinga
08:30AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
08:30AM	ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis GlobeNewswire
07:01AM	ChemoCentryx Rises on Update to FDA Vasculitis-Drug Filing TheStreet.com
05:40AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CCXI, WPG and HMPT ACCESSWIRE
Jul-05-21 11:36PM	SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ARRY, CCXI, PCT, WISH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
11:09PM	CHEMOCENTRYX 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI PR Newswire
11:00PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCXI, SKLZ and RLX ACCESSWIRE
10:35PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI Newsfile
06:18PM	CCXI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ChemoCentryx, Inc. Newsfile
04:30PM	ARRY, CCXI, PCT, WISH SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set ACCESSWIRE
04:15PM	JULY 6 DEADLINE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:38AM	CCXI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 6, 2021 in the Class Action Filed on Behalf of ChemoCentryx, Inc. Limited Shareholders Newsfile
10:10AM	Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for ChemoCentryx, Inc. Investors - CCXI PR Newswire
09:58AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - CCXI Newsfile
08:30AM	DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
05:40AM	CLASS ACTION UPDATE for CCXI, WISH and SPCE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
Jul-04-21 10:50PM	CHEMOCENTRYX 48 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess OF $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI Newsfile
12:19PM	CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds ChemoCentryx, Inc. Shareholders of Securities Fraud Class Action Lawsuit GlobeNewswire
11:15AM	FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action CCXI GlobeNewswire
10:30AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CCXI, PCT and WISH ACCESSWIRE
Jul-03-21 09:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI ACCESSWIRE
03:13PM	CCXI DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of ChemoCentryx, Inc. of Deadline in Securities Fraud Class Action Lawsuit Business Wire
Jul-02-21 10:50PM	SHAREHOLDER ALERT: CLAIMSFILER REMINDS ARRY, CCXI, PCT, WISH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
10:50PM	CHEMOCENTRYX 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI Business Wire
10:00PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc. and Encourages Investors to Contact the Firm Business Wire
04:10PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:36PM	LAWSUITS FILED AGAINST CCXI, HMPT and REKR - Jakubowitz Law Pursues Shareholders Claims ACCESSWIRE
02:50PM	Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. Newsfile
10:15AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CCXI, DNMR and REKR ACCESSWIRE
10:00AM	CCXI Looming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds ChemoCentryx, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 6, 2021 Newsfile
09:32AM	Is It Too Late to Buy ChemoCentryx Stock? Motley Fool
08:33AM	TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
05:40AM	CLASS ACTION UPDATE for CCXI, HMPT and REKR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
Jul-01-21 10:00PM	CHEMOCENTRYX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI Newsfile
02:10PM	5-Day Deadline Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:40PM	FINAL DEADLINE: ROSEN, A TOP RANKED INVESTOR RIGHTS LAW FIRM, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 6 Deadline in Securities Class Action - CCXI ACCESSWIRE
01:15PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCXI, RLX and RKT ACCESSWIRE
12:25PM	Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI) ACCESSWIRE
11:05AM	The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors PR Newswire
10:35AM	CLASS ACTION UPDATE for CCXI, ATER and RKT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
08:32AM	TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
05:40AM	SHAREHOLDER ALERT: CCXI RKT REKR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
Jun-30-21 10:12PM	SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ARRY, CCXI, PCT, WISH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
06:46PM	Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against ChemoCentryx, Inc. GlobeNewswire
04:38PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - CCXI Newsfile

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vifor (International) Ltd	10% Owner	Oct 12	Sale	39.43	4,000,000	157,720,000	5,194,085	Oct 13 07:05 PM
Tyree James L	Director	May 21	Option Exercise	0.00	4,660	0	17,729	May 24 08:19 PM
Parker Geoffrey M.	Director	May 21	Option Exercise	0.00	4,660	0	13,350	May 24 08:09 PM
Jain Rita	Director	May 21	Option Exercise	0.00	4,660	0	22,886	May 24 07:55 PM
Tyree James L	Director	May 21	Sale	9.76	2,454	23,956	15,275	May 24 08:19 PM
Butt Tausif	EVP, Chief Operating Officer	May 07	Buy	11.06	10,870	120,241	10,870	May 10 07:48 PM
Jain Rita	Director	Mar 27	Option Exercise	0.00	5,251	0	18,226	Mar 30 08:45 PM
Parker Geoffrey M.	Director	Mar 05	Sale	56.38	30,000	1,691,468	12,690	Mar 08 08:28 PM
Parker Geoffrey M.	Director	Mar 04	Sale	60.20	1,910	114,980	42,690	Mar 08 08:28 PM
Edwards Thomas A.	Director	Mar 02	Sale	70.06	1,100	77,063	119,857	Mar 03 08:33 PM
Kwan Pui San	Principal Acctg Officer	Mar 01	Option Exercise	10.46	3,347	35,012	6,579	Mar 01 08:54 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Mar 01	Option Exercise	10.24	33,092	338,972	118,918	Mar 03 08:39 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Mar 01	Sale	68.43	33,092	2,264,443	85,826	Mar 03 08:39 PM
Kwan Pui San	Principal Acctg Officer	Mar 01	Sale	68.52	3,347	229,335	3,232	Mar 01 08:54 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 09	Option Exercise	11.02	700	7,714	86,526	Feb 11 08:02 PM
Edwards Thomas A.	Director	Feb 09	Sale	70.03	400	28,014	120,957	Feb 11 07:52 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 09	Sale	69.66	700	48,765	85,826	Feb 11 08:02 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 08	Option Exercise	11.02	7,420	81,768	93,246	Feb 08 08:31 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 08	Sale	67.30	7,420	499,351	85,826	Feb 08 08:31 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 05	Option Exercise	11.02	805	8,871	86,631	Feb 08 08:31 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 05	Sale	67.07	805	53,994	85,826	Feb 08 08:31 PM
Kwan Pui San	Principal Acctg Officer	Feb 04	Option Exercise	10.46	3,347	35,012	6,579	Feb 08 08:25 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 04	Option Exercise	11.02	1,400	15,428	87,226	Feb 08 08:31 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 04	Sale	67.14	1,400	93,995	85,826	Feb 08 08:31 PM
Kwan Pui San	Principal Acctg Officer	Feb 04	Sale	65.00	3,347	217,555	3,232	Feb 08 08:25 PM
Edwards Thomas A.	Director	Feb 02	Sale	60.94	20,000	1,218,844	121,357	Feb 04 07:58 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jan 25	Option Exercise	11.02	1,375	15,152	87,201	Jan 27 08:22 PM
Kwan Pui San	Principal Acctg Officer	Jan 25	Option Exercise	9.70	4,184	40,564	7,416	Jan 27 07:25 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jan 25	Sale	67.03	1,375	92,172	85,826	Jan 27 08:22 PM
Kwan Pui San	Principal Acctg Officer	Jan 25	Sale	65.00	4,184	271,960	3,232	Jan 27 07:25 PM
Schall Thomas J.	President and CEO	Jan 01	Option Exercise	0.00	87,899	0	2,356,456	Jan 07 08:40 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jan 01	Option Exercise	0.00	30,333	0	135,263	Jan 07 08:32 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jan 01	Option Exercise	0.00	21,100	0	97,347	Jan 07 08:26 PM
Edwards Thomas A.	Director	Dec 28	Sale	61.50	10,782	663,093	141,357	Dec 29 06:58 PM
Edwards Thomas A.	Director	Dec 24	Sale	61.18	14,218	869,904	152,139	Dec 29 06:58 PM
Kwan Pui San	Principal Acctg Officer	Dec 15	Option Exercise	10.07	42,593	428,943	45,825	Dec 16 07:46 PM
Schall Thomas J.	President and CEO	Dec 15	Option Exercise	14.31	17,619	252,128	2,286,176	Dec 16 07:51 PM
Schall Thomas J.	President and CEO	Dec 15	Sale	65.01	17,619	1,145,450	2,268,557	Dec 16 07:51 PM
Kwan Pui San	Principal Acctg Officer	Dec 15	Sale	65.06	42,593	2,771,237	3,232	Dec 16 07:46 PM
Kwan Pui San	Principal Acctg Officer	Dec 14	Option Exercise	7.05	8,957	63,158	12,189	Dec 16 07:46 PM
Schall Thomas J.	President and CEO	Dec 14	Option Exercise	14.31	11,153	159,599	2,279,710	Dec 16 07:51 PM
Schall Thomas J.	President and CEO	Dec 14	Sale	65.03	11,153	725,246	2,268,557	Dec 16 07:51 PM
Kwan Pui San	Principal Acctg Officer	Dec 14	Sale	65.02	8,957	582,398	3,232	Dec 16 07:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience